In addition to AMXT1501, DFMO can also be used in combination with different polyamine transport inhibitors (Trimer PTIs) to increase granzase B and IFN-γ and activate effector T cells, ultimately inhibiting tumor-promoting microenvironment and increasing antitumor immune responses (67). This evidence concerns the gene IFNG and neoplasm.